Vertex Pharmaceuticals Incorporated Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Biotechnology | Market Cap: ₹1.1L Cr
- Vertex expects 2026 total revenue of $12.95 billion to $13.1 billion, representing 8%-9% growth. - Vertex reiterates 2026 total revenue guidance of $12.95 billion to $13.1 billion, reflecting 8%-9% growth year-over-year.
From Vertex Pharmaceuticals Incorporated's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹447.97
Market Cap
₹1.1L Cr
P/E Ratio
25.8
Revenue Rank
Margin Rank
How does Vertex Pharmaceuticals Incorporated rank in Biotechnology?
Compare Vertex Pharmaceuticals Incorporated against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 4- →Vertex expects 2026 total revenue of $12.95 billion to $13.1 billion, representing 8%-9% growth.
- →They anticipate JOURNAVX to more than triple prescriptions from 2025 levels (550,000), with revenue growth exceeding prescription growth.
- →JOURNAVX revenue in Q1 was $29 million, with strong growth drivers including field force expansion and payer coverage (240 million lives covered).
- →CASGEVY revenue ($43 million in Q1) is expected to contribute meaningfully to $500 million+ revenue from non-CF products, with strong visibility for 2026.
- →ALYFTREK continues to grow with label expansions, treatment of younger patients, and geographic rollout; has surpassed $1 billion cumulative revenue.
- →Vertex plans gross-to-net normalization by year-end with tapering patient support programs, accelerating revenue growth.
- →Renal portfolio (Pove and others) is positioned for multi-billion-dollar franchise potential based on promising clinical data.
📈 Profitability & Margins
Rank 3- →Vertex reiterates 2026 total revenue guidance of $12.95 billion to $13.1 billion, reflecting 8%-9% growth year-over-year.
- →Non-GAAP operating income for Q1 2026 was $1.31 billion, up from $1.18 billion in Q1 2025.
- →Non-GAAP net income increased by $93 million year-over-year to $1.1 billion.
- →Non-GAAP earnings per share (EPS) rose to $4.47 from $4.06 in Q1 2025, reflecting strong revenue growth and expense management.
- →Full-year 2026 non-GAAP effective tax rate expected in the range of 19.5% to 20.5%.
- →Non-GAAP operating expenses guided at $5.65 billion to $5.75 billion due to ongoing commercial and clinical investments.
- →Gross margin expected just under 86%, influenced by growing non-CF product mix and manufacturing investments.
- →Revenue growth driven by CF franchise expansion (ALYFTREK launch, label/global expansion), plus increasing contributions from CASGEVY and JOURNAVX.
- →Gross-to-net expected to normalize in second half of 2026, accelerating revenue faster than prescription growth.
🏗️ Capital Expenditure Plans
Yes- →Vertex is investing in manufacturing network and process development for various products, contributing to their non-GAAP operating expenses.
- →Continued investment in late-stage clinical pipeline and commercial infrastructure for new launches and revenue diversification is planned.
- →While specific capital expenditures (capex) amounts are not detailed, the company emphasizes targeted investments as part of operational expenses.
- →Vertex maintains a strong cash position ($13 billion) and demonstrates commitment to innovation investment alongside share repurchases.
- →The company is focused on expanding its commercial portfolio with emerging renal franchise and new disease areas, implying strategic investments in these segments.
- →There is no specific mention of new large-scale capital projects or facilities, but ongoing process and manufacturing advancements indicate steady capital investment.
💰 Fundraising & Capital Structure
No information- →No explicit mention of new fundraising through debt or equity in the Q1 2026 earnings call transcript.
- →The company ended Q1 2026 with $13 billion in cash and investments.
- →Executed $344 million share repurchase in Q1 2026, showing a focus on returning value to shareholders.
- →Primary focus remains on investing in innovation and strategic growth opportunities without indicating need for additional fundraising.
- →No stated plans for issuing new debt or equity during this period.
📋 Order Book & Pipeline
No information- →No explicit mention of a current or expected order book or pending orders in the provided pages.
- →The company highlights strong sales performance with over 1 million prescriptions written for JOURNAVX and more than 500 people initiating CASGEVY treatment.
- →ALYFTREK has exceeded $1 billion in cumulative revenue.
- →The company is on track to more than triple JOURNAVX prescriptions compared to 2025.
- →Coverage for JOURNAVX has expanded to 240 million lives, with ongoing progress in securing further coverage.
- →No specific future orders or backlog data disclosed; focus is on prescription growth and revenue acceleration as access improves and gross-to-net normalizes.
- →Pipeline products like Pove and others are progressing rapidly towards launch, indicating expected future commercial demand.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Frequently Asked Questions
What were Vertex Pharmaceuticals Incorporated Q2 FY26 results?
- Vertex expects 2026 total revenue of $12.95 billion to $13.1 billion, representing 8%-9% growth. - Vertex reiterates 2026 total revenue guidance of $12.95 billion to $13.1 billion, reflecting 8%-9% growth year-over-year.
What is Vertex Pharmaceuticals Incorporated share price analysis?
Vertex Pharmaceuticals Incorporated currently shows a neutral. The stock trades at a P/E of 25.8 with a market cap of $113,697. Investors should review the full earnings analysis for detailed insights.
Is Vertex Pharmaceuticals Incorporated planning capital expenditure?
- Vertex is investing in manufacturing network and process development for various products, contributing to their non-GAAP operating expenses.
Keep Vertex Pharmaceuticals Incorporated on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.